What's inside

Growing demand but shrinking headroom

Anti-amyloid therapy approvals have made amyloid PET a clinical prerequisite, with demand projected to grow up to 20-fold. Departments are expected to scan more patients, more often, while waiting lists are already long and scanner capacity hasn't changed.

One injection, two clinical answers

A single amyloid tracer injection can capture both amyloid burden and cerebral perfusion, potentially replacing a separate FDG-PET scan altogether. Fewer sessions per patient means more capacity for the next one, without adding infrastructure or cost.

Shorter scans that don't compromise the read

The barrier to dual-phase protocols is the image quality at short acquisition times. Deep learning denoising removes that barrier, recovering diagnostic confidence from 3-minute early-phase acquisitions and enabling leaner late-phase protocols that free scanner time and reduce tracer use.

‍